imaging. NP: Nanoparticle. OER: oxygen enhancement ratio. PEG: Polyethylene glycol. PIC: Polyion complex. PLGA: poly(lactic-co-glycolic acid). RBE: Relative biological effectiveness. TEM: Transmission electronic microscopy. 4 
Background
Remarkable progress has been made in the understanding and treatment of human cancer, resulting in a greatly improved survival rate for many patients. However, such achievements remain incomplete or out of reach for some hard-to-treat cancers, such as pancreatic cancer, glioblastoma or bone tumors. Chondrosarcomas are cartilaginous tumors which represent the second most common primary bone tumor in adults [1] . Chondrosarcomas are notoriously resistant to conventional radiation therapy and to chemotherapy, and complete surgical resection remains to this day the primary treatment. A number of patients experience relapse, metastasis or present unresectable disease with poor clinical outcome [2] .
Tumors are heterogeneous and are comprised of cells with various morphological and molecular features, including a subset of tumor-initiating dedifferentiated cells with selfrenewing abilities. These cancer stem cells (CSCs) are capable of reconstituting tumor heterogeneity, and a large amount of evidence strongly suggests that they may contribute to treatment resistance, relapse and metastasis [3] . CSCs have been identified in a number of tumors, including chondrosarcomas [4] . Several features of CSCs have been reported to explain their intrinsic radioresistance: lower levels of basal and radiation-induced reactive oxygen species (ROS), improved DNA damage repair activation and apoptosis inhibition or relative quiescent state [5] . New approaches are thus highly expected to address treatment-resistant tumors, which may include targeting CSCs.
In addition to conventional X-ray therapy, new high linear linear energy transfer (LET) radiation therapy modalities have emerged which might finally contribute overcoming treatment resistance, such as boron neutron capture therapy (BNCT) or carbon-ion particle therapy [6] . High LET therapies, alone or combined with other targeted treatments (like the PARP inhibitor talazoparib or the chemotherapeutic drug cisplatin), may be able to overcome CSC-related resistance [6] [7] [8] [9] [10] [11] . BNCT is an innovative experimental treatment modality that relies on the ability of 10 B to capture thermal neutrons, resulting in the release of high-linear energy transfer (LET) α ( 4 He) particles and lithium ( 7 Li) nuclei, with a path length shorter than 10 µm [12] . Therefore, it is crucial to maximize the concentration of boron-enriched compounds in tumor tissues while minimizing levels in surrounding normal tissues.
Furthermore, intracellular boron delivery should be achieved, due to the short path length of α ( 4 He) particles. Because BNCT releases high-LET radiation, it should provide improved relative biological effectiveness (RBE) and a lower oxygen enhancement ratio (OER), compared to conventional X-ray therapy. BNCT clinical trials have been performed on patients suffering from head and neck, brain, lung and liver cancers [12] , with some encouraging results in terms of overall survival, recurrence and metastasis. For those reasons, BNCT might also be an effective strategy for the treatment of radioresistant tumors, such as clear cell sarcoma (CSS) [13] , osteosarcoma [14] or chondrosarcoma.
Even though the first BNCT trials have been performed more than half a century ago, BNCT
has not yet become an established treatment modality, due to two main limiting factors [15] .
First, only two boron-delivery drugs are routinely used in BNCT clinical trial studies: sodium mercaptoundecahydrododecaborate (Na 2 10 B 12 H 11 SH; Na 2 10 BSH) and L-pboronophenylalanine (L-10 BPA). Reported tumor-to-normal tissue (T/N) ratio for BSH does not always reach 1. New advances are necessary to improve T/N ratio with low toxicity.
Second, the sole neutron sources traditionally available for BNCT were nuclear reactors.
Recent advances in nanotechnologies for drug delivery and the development of new accelerator-based neutron sources promise to overcome those limitations. Here, we report a new theranostic multi-functional boron-delivery system based on mesoporous silica nanoparticles (B-MSNs). We tested this system using an accelerator-based neutron beam for BNCT.
Nanoparticles (NPs) have recently emerged as a promising therapeutic tool for a variety of medical applications. NPs allow the encapsulation of therapeutic compounds with higher protection against metabolic degradation and the ability to control and target drug release preferentially in tumor tissues [16] . The accumulation of NPs in tumor tissues has been attributed to the poor alignment of neovascularization and lymphatic drainage in those areas, so called enhanced permeability (EPR) effect [17] . In particular, much attention has been devoted to the design of MSNs, which present a number of advantageous features: tunable size (usually 50 to 200 nm diameter), easy surface functionalization, large mesopore volume for efficient drug loading, in vitro and in vivo tolerance [18, 19] . They might therefore serve as ideal boron-delivery agents for BNCT.
Methods

Synthesis of mesoporous silica nanoparticles.
Synthesis steps are represented in Scheme S1.
-Synthesis of fluorescent MCM-41 (1) FITC (5.5 mg) was dissolved in 3 mL of ethanol under argon, then APTES (12 µL) was added and the reaction was stirred for 2 hours at room temperature. In a separate flask, CTAB (0.5 g) was dissolved in a mixture of MilliQ water (240 mL) and NaOH 2M (1.75 mL), and the mixture was stirred at 80°C. After 2 hours, the FITC-APTES solution was slowly added to the CTAB solution and the reaction was carried out at 80°C. After 2 hours, the reactional mixture was allowed to cool down to room temperature and the precipitate was filtrated with a fritted glass (porosity 3) and thoroughly washed with methanol. The powder was crushed and dried overnight under high vacuum.
-Grafting of APTES on nanoparticle surface (2) Nanoparticles obtained during step 1 -NP(1) -were suspended in methanol (50 mL) for 5 minutes, then APTES (3 mL) was added and the mixture was stirred overnight at room temperature. The suspension was centrifuged and washed three times with methanol, then allowed to dry for 2 hours under high vacuum.
-Surfactant removal (3) NP(2) were dispersed in a mixture of HCl (5 mL) and methanol (90 mL) and stirred at reflux for 24 hours. The suspension was centrifuged and washed with methanol, then allowed to dry for 2 hours under high vacuum.
-Ammonium neutralization and aggregates elimination (4) NP(3) were dispersed in DMSO (50 mL) then piperidine (12.5 mL) was added to neutralize ammonium. The mixture was bath sonicated for 40 minutes at room temperature, then centrifuged at 500 g for 10 minutes to eliminate aggregates. Nanoparticles were centrifuged and washed twice with DMSO and twice with methanol. The nanoparticles were dried under high vacuum for 2 hours.
-Grafting of MeO-PEG-COO-NHS (5 kDa) and Mal-PEG-COO-NHS (10 kDa) (5) NP(4) were dispersed in DMSO (50 mL), then Mal-PEG-NHS 10 kDa (5 mg) was added to the nanoparticles and stirred for 30 minutes. Next, MeO-PEG-NHS 5 kDa (95 mg) was added to the nanoparticle suspension. The mixture was stirred over night at room temperature, then centrifuged and washed three times with methanol. The nanoparticles were dried overnight under high vacuum.
-Grafting of APTES inside pores (6) NP (5) were dispersed in methanol (50 mL) for 15 minutes in sonication bath, then APTES (3 mL) was slowly added. The mixture was stirred for 24 hours at room temperature then the suspension was centrifuged and the nanoparticles are washed three times with methanol. The nanoparticles were dried overnight under high vacuum.
-Grafting of HOOC-CH2-Br inside the pores (7) NP (6) were maintained on a 12-hr light/12-hr dark cycle in a temperature-controlled (22°C) barrier facility with free access to water and a normal diet (CLEA Japan, Tokyo, Japan). Mice were allowed to acclimatize for 5 days before the experiment. 10 6 CH-2879 chondrosarcoma cells Cell culture and sorting of cancer stem cells. CH-2879 chondrosarcoma cells [20] and T/C 28AT immortalized chondrocytes [21] were grown in RPMI1640 and DMEM media, respectively (Nacalai, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) (Cosmo Bio, Tokyo, Japan) and antibiotic-antimycotic solution (Penicillin, Streptomycin, Amphotericin B. Gibco ThermoFisher, Carlsbad, CA, USA). Cultures were grown in 5% CO 2 at 95% humidity. As previously [22] , ALDH activity in the cells was measured by flow Table S1 . 100 µL/mL nanoparticles were administrated 3 hours before irradiation. Shortly before exposure to neutron beam, plated cells were trypsinized and transferred to 0.5 mL microtubes. After irradiation, cells were either processed for immediate analysis or replated for next day analysis, depending on the endpoint. Clonogenic assay. After irradiation, CH-2879 cells and CSCs were seeded in 6-well plates at defined densities, incubated for 10-14 days then stained as previously described [7] . Colonies with >50 cells were scored and surviving fractions were determined after correcting for the plating efficiency. 
Statistical
Results
We have developed multifunctional MSNs, which can serve as boron-delivery carrier and can be monitored for BNCT dosimetry (Figure 1 , Scheme S1). The mean diameter of inorganic core, as determined by transmission electronic microscopy (TEM), was around 100 nm ( Figure   1b ), within the range generally accepted for achieving optimal therapeutic effect [24] :
nanoparticles smaller than 10 nm in diameter encounter renal clearance, while bigger nanoparticles may not be able to penetrate and diffuse into the tumor. In order to improve biocompatibility and blood circulation time [25] , a layer of polyethylene glycol (PEG, 5kDa 95w%, 10 kDa 5 w%) was grafted onto the surface of nanoparticles by peptide bond (Figure   2a ). It is usually considered that grafting of PEG with molecular weight of at least 2 kDa is necessary to avoid clearing by the mononuclear phagocyte system [26] . PEG also allowed steric stabilization of the nanoparticles, which did not form significant aggregates in culture media [27] . After PEG grafting, the hydrodynamic radius of B-MSNs, measured by dynamic light scattering (DLS), was around 200 nm ( Figure 2b) .
The nanoparticles didn't show any significant toxicity in vitro ( Figure S3 ) or in vivo ( Figure S4 ) and exhibited good stability and dispersion properties, as confirmed by analysis of zeta potential values (consistently lower than -25 mV). MSNs are considered to be biocompatible, as toxicity can be observed only for high particle concentrations [28] .
Sufficient amounts of 10 B (about 20 μg/g weight or about 10 9 atoms/cell) need to be delivered to tumor cells for the success of BNCT [29] . Furthermore, because the track of a particles generated by boron-neutron capture is 10 µm at most, it is necessary that a sufficient proportion of 10 B penetrate inside cells for optimal efficiency. Large amounts of boron might be loaded into nanoparticle mesopores as o-carborane [30] , however there is a risk of carborane leakage and unpredictable boron distribution. Here, we propose to attach 10 [31, 32] . In addition, an Acp (aminohexanoic acid) moiety is grafted on the C-terminal portion of the peptide to serve as a spacer between the polycationic domain and the Cys residue for a better efficiency in the thiol-maleimide coupling strategy used. In the intact ACPP, the polyanionic peptide domain prevents uptake of the polycationic domain.
Matrix metalloproteinases (MMP) 2 and 9 (generally overexpressed in tumors [33] ) cleave the PLGLAG linker, releasing the cell-penetrating R8 portion grafted on the nanoparticle. Indeed, chondrosarcoma cells expressed higher levels of MMP-2 than normal chondrocytes ( Figure  3b ), leading to enhanced relative cellular uptake, compared to nanoparticles grafted only with polyethylene glycol (PEG) (Figures 3c and 3d ).
Unlike other radiation therapy modalities (X-rays or charged particle beams), calibration and dosimetry for BNCT relies on many parameters, including neutron beam properties and boron uptake in tumors. In this context, it is crucial to properly monitor the biodistribution of We have therefore also developed MSNs grafted with Gadolinium for in vivo visualization using magnetic resonance imaging (MRI) [34, 35] . These nanoparticles were injected into the tail vein of nude mice bearing xenograft chondrosarcoma tumors. Longitudinal (T1) and transverse (T2) relaxation times were measured for 24h in the tumor (Figures 4, S6 ). Due to its paramagnetic properties, gadolinium shortens T1 and T2 when it accumulates. While T1 values did not change significantly after injection, we observed a clear decrease in T2 values, reflecting nanoparticles tumor uptake. Relative lack of T1-weighted contrast is expected at high magnetic fields (11.7 T), as reported previously [36] . Accordingly, increased loading of gadolinium on nanoparticles led to changes in T2, but not T1 values ( Figure S5 ). Better overall T1-weighted contrast may be expected at lower fields in MRI systems for routine clinical use.
In order to verify the efficiency of our boron-delivery system in vitro, CH-2879 chondrosarcoma cells [20] and an ALDH+ radioresistant CSC subpopulation (around 1%) [37] (Figure 5a) were exposed to an epithermal neutron beam at the iBNCT facility [23] (Table S1 ).
Although apoptosis induction after 24h was limited (Figure 5c ), BNCT beam exposure resulted in significant DNA damage levels and lower clonogenic survival (Figure 5be ). BNCT exposure of cells in the absence of B-MSNs did not trigger DNA damage, suggesting that the biological effects of the neutron beam resulted from BNCT reaction. Comparison of survival curves may allow for a rough estimation of RBEs for dosimetry in this experimental system. Doses resulting in 10% survival (D10) were 5.86 Gy for X-rays and 0.42 mA.h (about 6.7x10 11 n/cm 2 ) for neutron beam.
Interestingly, while CSCs were more resistant to conventional X-ray therapy than the general CH-2879 cell population (Figure 5d ), no significant difference was observed in cells exposed to neutron beam (Figure 5e ), suggesting that high-LET radiation exposures such as BNCT might be more efficient at targeting CSCs than other treatment modalities, as observed for carbon-ion therapy [7] .
Discussion
The short range of alpha particles generated during the 10 B(n,α,γ) 7 Li nuclear reaction of BNCT provides the theorical ability to selectively target tumors cells. This could make BNCT an attractive treatment modality if improvements in boron-delivery and monitoring could be achieved [12] . Only two FDA-approved boron delivery compounds are currently adopted for clinical use: BPA and BSH [38, 39] . However, those two compounds lack specificity and do not allow the near-simultaneous measurement of boron biodistribution offered by theranostic delivery systems.
Our multi-functional B-MSNs may be a suitable delivery system for BNCT in some resistant cancers. Other boron-delivery strategies have included the encapsulation of boroncurcumin in poly(lactic-co-glycolic acid) (PLGA) nanoparticles [40] , the use of boron clustercontaining polyion complex (PIC) nanoparticles [41] , a boron-rich MAC-TAC liposomal system [42] , the delivery of dipeptides of BPA and Tyrosine by cancer-upregulated peptide transporters 1 and 2 (PEPT1, PEPT2) [43] , or the use of radiolabelled fluoroboronotyrosine (FBY) for Positron Emission Tomography (PET)-guided BNCT [44] . Our B-MSNs exhibit several advantageous features when compared with other organic and inorganic drug delivery systems: well-described synthesis steps and applications, easily tuneable particle and pore size, high flexibility for further functionalization, suitability for theranostic approaches [45] .
Furthermore, B-MSNs design and properties may be tailored based on tumor characteristics [46] .
Ultimately, clinical dose estimation for BNCT will require both the determination of neutron beam dose components and of boron uptake and biodistribution. Tsukuba-plan, a treatment planning system (TPS) for BNCT has been developed, which employs the Particle and Heavy Ion Transport code System (PHITS) as a Monte Carlo transport code [47, 48] .
Personalized dosimetry might also be possible by performing real-time detection (using Single
Photon Emission Computed Tomography -SPECT) of the gamma-rays emitted by excited 7 Li as a result of BNCT reactions [49] . The visualization of boron tumor uptake requires the functionalization of boron-delivery systems with a suitable molecular imaging reporter, like 18 F for PET or Fe/Gd for MRI, while optical imaging may be suitable only for small animal studies. Although PET is usually more sensitive, it requires the use of radioactive tracers,
whereas MRI provides high spatial resolution; both techniques are considered sufficiently sensitive for clinical BNCT applications [50] . For example, hepatocytes could be visualized by MRI when cells integrated at least 4 x 10 7 Gd complexes per cell [51] .
Overcoming treatment resistance might require an effective targeting of radioresistant CSCs [52, 53] . Therapeutic strategies against CSCs have included inhibition of WNT and NOTCH pathways, ablation using antibody-drug conjugates (ADCs) or epigenetic therapy, each with potential drawbacks or limitations [54] . High-LET radiation treatment, in combination with other targeted therapies, has shown favorable results in bypassing tumor and CSC radioresistance. Using our boron-delivery system, BNCT might be capable of efficiently targeting radioresistant CSCs in hard-to-treat tumors, such as chondrosarcoma. The ability of nanoparticle-based systems to target specific or diffuse tumor sites, as observed in malignant mesothelioma [55] , is also of particular interest for BNCT. The combination of different borondelivery approaches may also improve tumor boron targeting and treatment efficacy [56] .
Recently, a number of proton accelerator-based neutron sources have been commissioned for research and clinical use [57] , opening new perspectives for the potential development of BNCT as a viable new cancer therapy modality. 
Figure legends
Synthesis step
Boron Weight % 10 B % (8) BSH incorporation 1.63% ±0.49% 95% (9) ACPP grafting 1.27% ±0.24% 95% Table 1 . Quantification of Boron content by ICP-MS. Measurements were performed after BSH incorporation and after grafting of ACPP.
